This COVID-19 roundup includes coverage of the combination of amubarvimab and romlusevimab to manage COVID-19 infection, the association between COVID-19 and incident diabetes, and the effectiveness of...
After clinical trials to assess the safety, efficacy, and maintenance use, the FDA has approved the first oral treatment for moderately to severely active Crohn disease.
The researchers evaluated the impact of antirheumatic treatment in women who are pregnant with psoriatic arthritis and how such treatment affects pregnancy outcomes.
Researchers evaluated the response rate of gemcitabine in patients with platinum-resistant ovarian cancer given at a low dosage. Their research was presented at the Hematology/Oncology Pharmacy...
The FDA has approved a treatment for Friedreich ataxia after the results of randomized, placebo-controlled study indicate a strong effectiveness in treatment.
Researchers evaluated the impact an intensified dose of dolutegravir had on patients living with HIV. Their research was presented at the Conference on Retroviruses and Opportunistic Infections (CROI) 2023...
Researchers set out to determine the percentage of people in the United States with type 2 diabetes who meet the recommended criteria to use GLP-1 receptor agonists and SGLT-2 inhibitors as well as patients...
